Sumitomo Pharma Q2 FY2027: U.S. strength drives forecast upgrade

Sumitomo Pharma reported first-half revenue of ¥266.5 billion, up 17.3% year on year, while operating profit fell 56.0% to ¥42.3 billion and net income attributable to owners of the parent declined 61.3% to ¥38.2 billion. Growth in the U.S. drove higher revenue, but profit fell sharply as the company lapped a one-off gain from the previous year.

• U.S. product sales expanded: Sales of Orgovyx and Gemtesa increased, while the weaker yen also helped lift U.S. revenue by ¥40.8 billion year on year to ¥197.8 billion.
• Lapse of prior-year gain: In the year-earlier period, Sumitomo Pharma recorded a gain on the transfer of equity interests in an affiliate under other income, following the sale of part of its Asian business. There was no comparable income this period.
• Higher selling and R&D expenses: Spending on promotion rose as the company expanded U.S. sales, while research and development costs increased to advance clinical trials, including in oncology.

Gross profit did not increase significantly from a year earlier despite higher revenue, weighing on earnings. With sales growth not translating directly into profit growth, investors will be watching whether expanding U.S. product sales can absorb rising promotional and development costs.

Sumitomo Pharma changed its reportable segments to a single Pharmaceuticals segment starting this interim period. The figures below describe regional sales trends cited by the company, not results by its current reportable segments. Growth in the U.S. lifted overall revenue, while the effects of the partial sale of the Asian business continued to weigh on other regions.

• U.S.: Revenue increased by ¥40.8 billion year on year to ¥197.8 billion. Although the previous year included a sales milestone payment for Orgovyx, expanded sales of the drug and Gemtesa, along with the weaker yen, drove growth.
• Japan: Revenue rose by ¥1.8 billion year on year to ¥44.6 billion. The end of sales partnerships for Equa and EquMet was offset by the start of in-house sales for Xeplion and Xeplion TRI, as well as growth in Twymeeg.
• Other: Revenue fell by ¥3.2 billion year on year to ¥24.1 billion. Sales to Europe increased, but the impact of the prior-year sale of part of the Asian business was greater.

The move to a single segment reflects a structure that gives the company direct involvement in managing its core U.S. products, and the reality that it allocates resources and evaluates performance across the pharmaceutical business as a whole. Investors will be watching not only regional sales trends but also how the company deploys global research, development and sales resources.

Sumitomo Pharma raised its forecast for the fiscal year ending March 2027. The revision reflects expectations that sales, particularly of Gemtesa in the U.S., will exceed the company’s plan, as well as a change in its assumed exchange rate from ¥155 to ¥157 per dollar.

The company expects higher revenue to lift gross profit, but also anticipates increased costs to support sales expansion, so it did not raise its core operating profit forecast as much as its revenue outlook. Revised operating profit and net income remain below the previous year’s actual results. Balancing sales growth with cost control will be key to meeting the full-year targets.

Total assets at the end of the interim period increased by ¥46.5 billion from the previous fiscal year-end, supported by a public share offering and other factors. The ratio of equity attributable to owners of the parent, a measure comparable to the equity ratio, rose to 50.7%. Lower borrowings also contributed to an improvement in the company’s financial position.

• Operating cash flow: Cash inflow was ¥16.7 billion, down ¥1.4 billion from ¥18.0 billion in the year-earlier period.
• Investing cash flow: Cash inflow was ¥0.5 billion, down from ¥27.6 billion in the year-earlier period, which included proceeds related to the loss of control of a subsidiary.
• Financing cash flow: Cash inflow was ¥17.6 billion. Proceeds from share issuance offset outflows from debt repayments.
• Dividends: The interim dividend was ¥0, while the forecast for the year-end dividend is ¥15 per share. The full-year dividend forecast was revised to ¥15 from ¥0 in the previous year.

Proceeds from the public share offering contributed to financing cash flow, increased equity and helped reduce liabilities. The company is rebuilding financial capacity through the share issuance while also signaling a return to year-end dividends. How it balances investment for growth with shareholder returns will be an important consideration.

Research and development expenses rose 35.6% year on year to ¥23.8 billion. Even on a core basis, excluding the impact of restructuring costs included in the year-earlier period, expenses increased 35.9%, signaling an effort to accelerate clinical development.

• Oncology: In April, Sumitomo Pharma began a pivotal Phase 2 trial of enzomenib, also known as DSP-5336, for acute myeloid leukemia.
• Clinical trial progress: In June, the company completed enrollment of the cases required for an interim analysis in a pivotal Phase 2 trial for acute leukemia with KMT2A gene rearrangement.

Higher R&D spending was one factor weighing on interim-period earnings, but it is also investment in developing future product candidates. Beyond trial progress, development outcomes and the time needed to bring products to market will determine whether the pipeline can deliver growth beyond the company’s core U.S. products.

U.S. product sales and the weaker yen supported revenue in the interim period, but profit fell sharply from a year earlier. Investors will need to assess not only sales growth but also how foreign exchange, promotional expenses and clinical development progress affect earnings and the full-year forecast.

• Dependence on U.S. products: Orgovyx and Gemtesa in the U.S. were the main drivers of revenue growth. Sales below plan could affect the company’s ability to meet its full-year revenue and profit forecasts.
• Currency fluctuations: The full-year assumption was changed to ¥157 per dollar. A stronger yen could weigh on yen-denominated revenue and profit.
• Rising sales and R&D expenses: Promotional spending to expand sales and clinical trial costs are increasing. If sales growth does not outpace the rise in costs, profit recovery will be limited.
• Clinical development uncertainty: The commercial outlook for drugs in development may change depending on trial results and progress. The timing of returns on R&D investment is also uncertain.

The company says its forecasts are based on information and assumptions available at the time of announcement, and actual results may differ due to a range of factors.